Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported Q2 2026 total revenue of $83.2 million, up 19% year-over-year, with net product sales of LUPKYNIS growing 19% to $79.4 million. Net income increased 74% to $37.4 million, or $0.28 per diluted share, while operating cash flows rose 19% to $52.5 million. The company reiterated its full-year 2026 revenue guidance of $315 million to $325 million and ended the quarter with $443.1 million in cash and investments after repurchasing $74.9 million of shares in the first half of the year.
Key figures
- Eps
- 0.28
- Revenue
- 83200000
- Guidance
- 2026 total revenue $315 million to $325 million
- Revenue Yoy
- 19%
- Net income
- 37400000
- Cash position
- 443100000
- Buyback amount
- 74900000
- Net product sales
- 79400000
- Shares repurchased
- 5000000
- Operating cash flow
- 52500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.